Related Experiment Video
Updated: Jan 18, 2026

Author Spotlight: Establishing MASLD Cell Models for Investigating Disease Mechanisms and the Lipid-Lowering Effects of Koumiss
Published on: July 19, 2024
Dietary vitamin E intake in metabolic dysfunction-associated steatotic liver disease and all-cause/cause-specific
Donghee Kim1, Pojsakorn Danpanichkul2, Karn Wijarnpreecha3,4
1Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Stanford, California.
Aims:
We investigated the independent association between dietary vitamin E intake among individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) and all-cause and cause-specific mortality in a representative sample of the USA.
Methods:
We used the 2007-2014 US National Health and Nutrition Examination Survey with mortality follow-up through 2019 (median: 8.6 years). Cox regression models were used to assess the association between dietary vitamin E intake in MASLD and all-cause and cause-specific mortality.
Results:
Among the 10 193 individuals with MASLD (mean age: 46.8 years and male: 48.0%), greater dietary vitamin E intake was correlated with a gradual reduction in the risk of all-cause mortality, which remained significant after adjustment for clinical and metabolic risk factors (hazard ratio: 0.68, 95% confidence interval: 0.50-0.94 for the fourth quartile compared with the first quartile; P for trend = 0.018). This association remained more pronounced in older populations, males, and non-Hispanic Whites than in their counterparts. Increased dietary vitamin E intake demonstrated trends associated with reduced cancer-related mortality.
Conclusion:
Higher dietary vitamin E intake in MASLD was associated with a lower risk of all-cause mortality.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Vitamins
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Lipids: Dietary Sources and Requirements
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

